Download CURRICULUM VITAE (abbreviated)

CURRICULUM VITAE (abbreviated)
GREGORY Y. H. LIP
UNIVERSITY EDUCATION:
University of Glasgow, Glasgow G12 8QQ.
Graduated July 1988 with the degrees of M.B., Ch.B. (with commendation)
with the following prizes for the most distinguished graduate in medicine and surgery of the year:
- the BRUNTON MEMORIAL PRIZE and the Robert Fullerton Prize.
MEMBERSHIP OF THE ROYAL COLLEGES OF PHYSICIANS M.R.C.P.(U.K.) March 1991
DIPLOMA OF FORENSIC MEDICINE (DFM) with Class Prize. September 1993
DOCTOR OF MEDICINE (M.D.) University of Glasgow, September 1994
FELLOW OF THE AMERICAN COLLEGE OF CARDIOLOGY (F.A.C.C.) August 1996
FELLOW OF THE EUROPEAN SOCIETY OF CARDIOLOGY (F.E.S.C.) June 1997
FELLOW OF THE ROYAL COLLEGE OF PHYSICIANS OF EDINBURGH (F.R.C.P.Edin) Sept 1998
FELLOW OF THE ROYAL COLLEGE OF PHYSICIANS AND SURGEONS OF GLASGOW (F.R.C.P.Glasg) 1999
FELLOW OF THE ROYAL COLLEGE OF PHYSICIANS OF LONDON (F.R.C.P.Lond) May 2001
******************************************************************
PRESENT APPOINTMENT:
Professor of Cardiovascular Medicine, University of Birmingham Centre for Cardiovascular Sciences, City Hospital, Birmingham, UK
Visiting Professor of Haemostasis Thrombosis & Vascular Sciences, Aston University, Birmingham, UK (2009-);
Adjunct Professor of Cardiovascular Sciences, Thrombosis Research Unit, Aalborg University, Denmark (2011-)
Consultant Cardiologist, Sandwell and West Birmingham Hospitals NHS Trust (1996-)
My present appointment allows full clinical responsibilities in cardiovascular medicine (including invasive and non-invasive cardiology); as
well as acute general medicine, teaching and cardiovascular research. I have a clinical academic job plan, with a 50:50 academic:clinical
timetable, with responsibilities for coronary care, inpatient wards, outpatients, etc. I run consultant-led specialist services for atrial
fibrillation and hypertension. In addition, I participate in a 24/7 on call service rota for primary angioplasty for acute myocardial infarction.
My research interests are in atrial fibrillation, hypertension, stroke, antithrombotic therapy, hormone replacement therapy & cardiovascular
risk and ethnic differences in vascular disease; in addition, I lead a laboratory-based research group (the Haemostasis Thrombosis and
Vascular Biology Unit) studying thrombogenesis, atherogenesis and endothelial dysfunction in cardiovascular disease and stroke.
PREVIOUS APPOINTMENTS:
August 1989 to July 1991 Senior House Officer Medical Rotation : Western Infirmary / Gartnavel General Hospital / Vale of Levan DGH
August,1991 to July,1993 Clinical Research Fellow in the Department of Cardiology, Stobhill General Hospital; and the Haemostasis,
Thrombosis and Vascular Medicine Unit, University Department of Medicine, Royal Infirmary, Glasgow.
August,1993 to July,1995 Registrar (and Hon Postdoctoral Research Fellow) In Medicine & Cardiology - University Department of
Medicine and Department of Cardiology, City Hospital, Birmingham.
August/September,1995 to November, 1996 Senior Registrar in Cardiology, West Midlands Region, based at Walsgrave Hospital,
Coventry (and Lecturer in Medicine, University Department of Medicine, City Hospital, Birmingham)
Other responsibilities: Editor in Chief (Clinical), Thrombosis & Haemostasis; Guest editor, Circulation; Clinical adviser to the NICE
national guidelines on atrial fibrillation management; Writing Committee, 8 th American College of Chest Physicians Guidelines on
Antithrombotic Therapy; Writing Committee for ESC guidelines on atrial fibrillation [2010] and heart failure [2011]; Member of various
Editorial Boards (Circulation, JACC, European Heart Journal, Heart, ATVB, Hypertension) and research grant reviewer (Medical Research
Council, British Heart Foundation, Wellcome Trust, etc).
PUBLICATIONS:
M.D THESIS “A study of thrombogenesis in atrial fibrillation and left ventricular dysfunction.” (University of Glasgow, 1994)
~1610 publications on Medline (including those "in press") on angiology, markers of thrombogenesis and atherogenesis, atrial fibrillation,
hypertension, stroke, ethnic differences in cardiovascular disease, clinical epidemiology, etc.
H-index: 87
Selected recent or key publications
Banerjee A, Fauchier L, Vourc'h P, Andres CR, Taillandier S, Halimi JM, Lip GY. Renal impairment and ischaemic stroke risk assessment in
patients with atrial fibrillation: The Loire Valley Atrial Fibrillation Project. J Am Coll Cardiol. 2013 Mar 21. doi:pii: S07351097(13)01113-3. 10.1016/j.jacc.2013.02.035.
Friberg L, Benson L, Rosenqvist M, Lip GY. Assessment of female sex as a risk factor in atrial fibrillation in Sweden: nationwide
retrospective cohort study. BMJ. 2012 May 30;344:e3522.
Rasmussen LH, Larsen TB, Graungaard T, Skjøth F, Lip GY. Primary and secondary prevention with new oral anticoagulant drugs for stroke
prevention in atrial fibrillation: indirect comparison analysis. BMJ. 2012 Nov 5;345:e7097. doi:10.1136/bmj.e7097.
Friberg L, Rosenqvist M, Lip GY. Net clinical benefit of warfarin in patients with atrial fibrillation: a report from the Swedish atrial
fibrillation cohort study. Circulation. 2012 May 15;125(19):2298-307. Epub 2012 Apr 18.
1
Friberg L, Rosenqvist M, Lip GY. Evaluation of risk stratification schemes for ischaemic stroke and bleeding in 182 678 patients with atrial
fibrillation: the Swedish Atrial Fibrillation cohort study. Eur Heart J. 2012 Jun;33(12):1500-10.
Apotolakis S, Lane D, Gao Y, Buller H, Lip GY. Performance of the HEMORR2HAGES, ATRIA and HAS-BLED bleeding risk prediction
scores in anticoagulated patients with atrial fibrillation: The AMADEUS study. J Am Coll Cardiol 2012;60:861-7
Lip GY, Larsen TB, Skjøth F, Rasmussen LH. Indirect Comparisons of New Oral Anticoagulant Drugs for Efficacy and Safety When Used
for Stroke Prevention in Atrial Fibrillation. J Am Coll Cardiol. 2012;60:738-46
Lip GY, Frison L, Halperin JL, Lane DA. Comparative validation of a novel ris score for predicting bleeding risk in anticoagulated patients
with atrial fibrillation: the HAS-BLED (Hypertension, Abnormal Renal/Liver Function, Stroke, Bleeding History or Predisposition, Labile
INR, Elderly, Drugs/Alcohol Concomitantly) score. J Am Coll Cardiol. 2011 Jan 11;57(2):173-80.
Boriani G, Botto GL, Padeletti L, Santini M, Capucci A, Gulizia M, Ricci R, Biffi M, De Santo T, Corbucci G, Lip GY; Italian AT-500
Registry Investigators. Improving stroke risk stratification using the CHADS2 and CHA2DS2-VASc risk scores in patients with paroxysmal
atrial fibrillation by continuous arrhythmia burden monitoring. Stroke. 2011 Jun;42(6):1768-70.
Pisters R, Lane DA, Nieuwlaat R, de Vos CB, Crijns HJ, Lip GY. A novel user-friendly score (HAS-BLED) to assess 1-year risk of major
bleeding in patients with atrial fibrillation: the Euro Heart Survey. Chest. 2010 Nov;138(5):1093-100.
Olesen J, Lip GY, Kamper AL, Hommel K, Kober L, Lane DA, Lindhardsen J, Gislason GH, Torp-Pedersen C. Stroke and Bleeding in
Atrial Fibrillation with Chronic Kidney Disease. N Engl J Med 2012;367:625-35.
Olesen JB, Lip GY, Hansen ML, Hansen PR, Tolstrup JS, Lindhardsen J, Selmer C, Ahlehoff O, Olsen AM, Gislason GH, Torp-Pedersen C.
Validation of risk stratification schemes for predicting stroke and thromboembolism in patients with atrial fibrillation: nationwide cohort
study. BMJ. 2011 Jan 31;342:d124. doi: 10.1136/bmj.d124. PubMed PMID: 21282258
Reviews
Lip GY, Tse HF, Lane DA. Seminar – Management of atrial fibrillation. Lancet 2012;379(9816):648-61
Banerjee A, Marín F, Lip GY. A new landscape for stroke prevention in atrial fibrillation: focus on new anticoagulants, antiarrhythmic drugs,
and devices. Stroke. 2011 Nov;42(11):3316-22.
Marinigh R, Lane DA, Lip GY. Severe renal impairment and stroke prevention in atrial fibrillation: implications for thromboprophylaxis and
bleeding risk. J Am Coll Cardiol. 2011 Mar 22;57(12):1339-48.
Marinigh R, Lip GY, Fiotti N, Giansante C, Lane DA. Age as a risk factor for stroke in atrial fibrillation patients implications for
thromboprophylaxis: Implications for thromboprophylaxis. J Am Coll Cardiol. 2010 Sep 7;56(11):827-37.
Guidelines and Consensus Documents
Lip GY, Ponikowski P, Andreotti F, Anker SD, Filippatos G, Homma S, Morais J, Pullicino P, Rasmussen LH, Marin F, Lane
DA. Thrombo-embolism and antithrombotic therapy for heart failure in sinus rhythm. A Joint Consensus Document from the ESC Heart
Failure Association and the ESC Working Group on Thrombosis. Eur J Heart Fail. 2012 May 19. [Epub ahead of print] PubMed PMID:
22611046.
You JJ, Singer DE, Howard PA, Lane DA, Eckman MH, Fang MC, Hylek EM, Schulman S, Go AS, Hughes M, Spencer FA, Manning WJ,
Halperin JL, Lip GY; American College of Chest Physicians. Antithrombotic therapy for atrial fibrillation: Antithrombotic Therapy and
Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest. 2012
Feb;141(2 Suppl):e531S-75S.
Lip GY, Andreotti F, Fauchier L, Huber K, Hylek E, Knight E, Lane D, Levi M, Marín F, Palareti G, Kirchhof P. Bleeding risk assessment
and management in atrial fibrillation patients. Executive Summary of a Position Document from the European Heart Rhythm Association
[EHRA], endorsed by the European Society of Cardiology [ESC] Working Group on Thrombosis. Thromb Haemost. 2011 Nov
30;106(6):997-1011.
Lip GY, Huber K, Andreotti F, Arnesen H, Airaksinen JK, Cuisset T, Kirchhof P, Marín F; Consensus Document of European Society of
Cardiology Working Group on Thrombosis. Antithrombotic management of atrial fibrillation patients presenting with acute coronary
syndrome and/or undergoing coronary stenting: executive summary--a Consensus Document of the European Society of Cardiology Working
Group on Thrombosis, endorsed by the European Heart Rhythm Association (EHRA) and the European Association of Percutaneous
Cardiovascular Interventions (EAPCI). Eur Heart J. 2010 Jun;31(11):1311-8.
Camm AJ, Lip GY, De Caterina R, Savelieva I, Atar D, Hohnloser SH, Hindricks G, Kirchhof P. 2012 focused update of the ESC
Guidelines for the management of atrial fibrillation: An update of the 2010 ESC Guidelines for the management of atrial fibrillation *
Developed with the special contribution of the European Heart Rhythm Association. Eur Heart J. 2012 Nov;33(21):2719-47.
Camm AJ, Kirchhof P, Lip GY, Schotten U, Savelieva I, Ernst S, Van Gelder IC, Al-Attar N, Hindricks G, Prendergast B, Heidbuchel H,
Alfieri O, Angelini A, Atar D, Colonna P, De Caterina R, De Sutter J, Goette A, Gorenek B, Heldal M, Hohloser SH, Kolh P, Le Heuzey JY,
Ponikowski P, Rutten FH. Guidelines for the management of atrial fibrillation: the Task Force for the Management of Atrial Fibrillation of
the European Society of Cardiology (ESC). Eur Heart J. 2010 Oct;31(19):2369-429.
Singer DE, Albers GW, Dalen JE, Fang MC, Go AS, Halperin JL, Lip GY, Manning WJ; American College of Chest Physicians.
Antithrombotic therapy in atrial fibrillation: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th
Edition). Chest. 2008 Jun;133(6 Suppl):546S-592S.
~600 published abstracts - presented at national & international meetings, including the American College of Cardiology, American Heart
Association, European Society of Cardiology, International Society of Hypertension, International Society of Thrombosis and Haemostasis,
British Society of Haematology, European Society of Hypertension, British Cardiac Society, Medical Research Society, etc.
2
STATEMENT OF ACHIEVEMENTS
The focus of my contribution has been on clinical cardiovascular research, with particular focus on atrial fibrillation (AF) which is the
commonest sustained cardiac rhythm disorder. AF confers a substantial risk of stroke and thromboembolism. My research work has had
major impact on contemporary national/international treatment guidelines on AF, in relation to the epidemiology and pathophysiology of
thromboembolism in AF, as well as the clinical assessment of stroke and bleeding risk in AF.
RESEARCH
My major research contributions have been to define the clinical epidemiology of AF and pathophysiology of thrombosis in this arrhythmia.
My work had led to major changes in national and international treatment guidelines for this condition.
My research has defined the epidemiology of this common arrhythmia in European (eg. Rotterdam study, Belgrade AF project, Loire Valley
AF Project, Danish Diet Cancer & Health study, 2010-) and Far East (J-TRACE in Japan, Chin-Shan Community Cohort Study in Taiwan;
both 2011-) populations, and the value of screening for the condition in primary care (the SAFE study). The west Birmingham Atrial
Fibrillation project and E-ECHOES (Ethnic–Echocardiographic Heart of England study, funded by the BHF; 2009-) have described AF
amongst the local Birmingham ethnic minority populations. The MRC-funded Birmingham Atrial Fibrillation Treatment of the Aged
(BAFTA) trial has established the value of oral anticoagulation for stroke prevention in the elderly (age >75), and the limited role of aspirin
(2007-onging analyses).
My research has investigated the impact of risk factors for stroke and bleeding in patients with, leading to my development and validation of
the CHA2DS2-VASc and HAS-BLED scores for assessing stroke and bleeding risk, respectively.
These scores have helped clinicians
looking after this common condition, to assess stroke risk and identify ‘truly low risk’ patients who do not need antithrombotic therapy,
whilst those with ≥1 stroke risk factors can be considered for oral anticoagulation therapy. This work into improving AF clinical management
won the Heart Rhythm UK‘Arrhythmia Alliance Team of the Year Award 2012'.
These 2 risk scores are now used in international treatment guidelines (European Society of Cardiology (ESC), Canadian Cardiovascular
Society (CCS), narrative version in 9th American College of Chest Physicians (ACCP) guidelines). Indeed, my research has had a major
impact on recommendations in AF guidelines issued by the UK National Institute for Health & Clinical Excellence (NICE, 2006), as well as
the ESC (2010), CCS (2011) and ACCP (2012). My research work has also informed European consensus guidelines on the optimal
management of anticoagulated AF patients who present with an acute coronary syndrome ± undergo coronary intervention/stenting (ESC,
2010), as well as the assessment/management of bleeding in AF patients (European Heart Rhythm Association (EHRA), 2011).
The concept of ‘atrial fibrillation is a prothrombotic or hypercoagulable state’ was first proposed by myself in a Lancet article in 1996. My
ongoing work has validated biomarkers of thromboembolism and vascular biology in cardiovascular disease (esp AF) as prognostic indices,
and such biomarkers have been used in the assessment and investigation of AF, and the study of new antithrombotic drugs by industry
(various ongoing studies, 2009-), as surrogate biomarkers of clot formation in AF.
Since 2009, my research group has ongoing major collaborations nationally (Aston University, Birmingham; University of London, UK) and
internationally (Rotterdam Study, the Netherlands; University of Maastricht, the Netherlands; Aalborg University, Denmark; University of
Murcia, Spain; University of Iowa, USA; Tokai University, Tokyo, Japan; University of Belgrade, Serbia; University of Tours, France;
University of Hong Kong, China; National Taiwan University, Taiwan).
I currently have joint programme grants with the University of London (BHF/Stroke Association – CROMIS-2 study, c£1m; 2010-ongoing)
and Aalborg University, Denmark (Danish National Research Council – epidemiology and pathophysiology of AF, c£2.5m; 2010-ongoing).
I have established and led the Centre for Cardiovascular Sciences base at City Hospital, Birmingham since 2009 – this is now recognised as a
major centre for clinical research into cardiovascular disease, and has attracted applications from numerous post-doctorate fellows from
overseas (2010-2011, current fellows are from Spain, Greece, Denmark, Belarus, Italy).
I have successfully attracted major grant funding (total - £11+m cumulative) from the British Heart Foundation, Heart Research UK, Medical
Research Council, NHS HTA Programme, Arthritis Research Council, Action Medical Research, Peel Medical Research Trust, etc). I have
acted as principal investigator for various projects in my department and successfully supervised/co-supervised approximately 40
postgraduate thesis leading to MD, PhD, Masters, etc degrees.
I have been a member of the University of Birmingham Centre for Cardiovascular Sciences (CCS) research strategy committee since its
establishment approx 6 years ago, and from May 2011, have been appointed co-chairman (with Prof S P Watson) of this committee. This
committee now has a high priority ethos of integration of the various research groups within the CCS and facilitating collaborations and joint
projects/grants/fellows.
Based on my research, I have been conferred titles of Visiting Professor of Haemostasis Thrombosis & Vascular Sciences, Aston University,
Birmingham, UK (2009); and based on research and teaching, as Adjunct Professor of Cardiovascular Sciences, Thrombosis Research Unit,
Aalborg University, Denmark (2011).
I have regular invitations to deliver keynote/plenary lectures at international/major national meetings, for example, the ‘State of the Art’
keynote plenary lecture at the 2011 International Society of Thrombosis & Haemostasis (the main international thrombosis meeting in the
field). Also, as ‘invited keynote lecturer’ at the Japanese College of Cardiology (September 2011) and Venice Arrhythmia (October 2011).
I am Editor in Chief (Clinical Studies) [2010-] of ‘Thrombosis & Haemostasis’ (Impact factor 4.701, and rising) and Editor in Chief of
‘Journal of Human Hypertension’ [2007-] (Impact Factor 2.3). I also regularly act as Guest Editor for ‘Circulation’ (Impact Factor 10.8 – the
top journal in cardiology; 2009-). I am an Associate Editor for ‘Europace’ (the main journal for the European Heart Rhythm Association;
2009-).
I am on the editorial boards of many of the main journals in the field, including the following (all with Impact Factor >4.0): Journal of the
American College of Cardiology (IF10.4), Atherosclerosis Thrombosis & Vascular Biology, Hypertension, Heart, American Journal of
Cardiology, American Heart Journal, Chest, Journal of Cardiac Failure, American Journal of Medicine, Nature Reviews Cardiology,
International Journal of Cardiology, etc.
I have regularly been invited to organise and/or deliver masterclasses and practice-based symposia at national (eg BMJ Masterclass 2010,
Royal College of Physicians of Edinburgh teach-ins, etc) and international meetings (eg. European Society of Cardiology, Europace,
theheart.org symposia, etc) on AF and/or thrombosis. I have been involved (expert speaker, or workshop lead) in ESC regulatory and
implementation workshops in relation to the ESC atrial fibrillation guidelines (2010). I was co-organiser for the 3rd Atrial Fibrillation
Competence NETwork/European Heart Rhythm Association consensus conference on ‘Comprehensive risk reduction in patients with atrial
fibrillation: emerging diagnostic and therapeutic options’ (2010). I was workshop leader and keynote speaker on the 1st (Outcome parameters
3
for trials in atrial fibrillation, 2007) and 2 nd (Early and comprehensive management of atrial fibrillation, 2009) EHRA/AF-NET consensus
conferences, which have defined clinical practice in their respective areas.
I was previously clinical adviser to the UK NICE guidelines on atrial fibrillation (2006) and the subsequent NICE
implementation/commissioning committee on anticoagulation for AF (2007). I was the clinical expert to NICE, also representing the British
Cardiovascular Society, on its evaluation of dabigatran for stroke prevention in AF (2011).
I represented the British Cardiovascular Society on a Working Party of the Royal College of Physicians and Association of British
Neurologists on local adult neurology services in district general hospitals (2009-2011).
I recently Chaired a working party which developed an independent consensus guideline ‘Guidance on the prevention of stroke and systolic
embolism in patients with atrial fibrillation’ (http://www.eguidelines.co.uk/ October 2011).
I have regularly acted as Chair of task forces compiling position/consensus documents for the European Society of Cardiology (ESC)
Working Group on Thrombosis, European Heart Rhythm Association (EHRA), etc. I was Chair of a joint ESC Working Group on
Thrombosis/EHRA/European Association Percutaneous Cardiovascular Interventions Consensus Document on management of AF patients
presenting with an acute coronary syndrome ± undergoing angioplasty/stenting (2010), and more recently, Chaired an EHRA position
document on bleeding risk assessment and management in AF patients (2011).
I was Chair of a task force of the European Heart Failure Association, which is writing a consensus document on antithrombotic therapy in
heart failure (2012), which includes systematic reviews that will inform the new European treatment guidelines in heart failure.
I am currently Chairmain of the large EuroObservational Research Programme on Atrial Fibrillation, for the European Society of Cardiology
– this is a multinational European clinical practice survey, which will deliver 1 st results in 2012.
I am on the writing committee for guidelines for the American College of Chest Physicians international guidelines on antithrombotic therapy
(7th, 8th and 9th editions), and new international guidelines from the ESC (atrial fibrillation 2010, heart failure 2012, atrial fibrillation focussed
update 2012). I am the section lead for ‘stroke prevention’ for the ESC AF guidelines of 2010 and the focussed update of 2012. For the 9 th
ACCP guideline(2012), I was appointed as ‘content expert’ (=’deputy editor’) for the AF guideline section.
I am a writing committee member of an ESC Working Group on Thrombosis task force on Anticoagulants (2011-2012), producing a series of
expert reviews and consensus documents on the use of anticoagulants in heart disease.
I have had significant engagement with industry, especially in areas related to AF and thrombosis, acting as steering committee Chair of
Phase 2 or 3 clinical trials (2009-) or Phase 4 studies (2011-), which have been conduted on a multicentre, international basis. These include
studies by Astellas (2009-), AstraZeneca (2009), Boehringer Ingelheim (2010-), etc.
TEACHING
In 2011, I was Chair of a working group on vertical integration of undergraduate cardiology teaching for the University of Birmingham. I
have also advised on the new Year 4 curriculum on clinical cardiology (2011).
In October 2011, I was an invited teacher on the 2–day PhD seminar teaching programme for Aalborg University. As mentioned above, I
have recently been conferred the title of Adjunct Professor in Aalborg University, Denmark – for research and teaching.
I frequently give invited plenary lectures or masterclasses at various local/national (eg.BMJ Masterclass, Royal Colleges in UK) &
international meetings (eg. European Society of Cardiology, ESC). I regularly chair/lecture at educational symposia (eg. 'Meet the Experts',
'Focus sessions', at the ESC, American Heart Association, American College of Cardiology, etc). I have taught on ESC/EHRA teaching
courses, for example, on cardiac arrhythmias. I am a committee member of the Hot Topics symposia committee of the Royal College of
Physicians of Edinburgh (2009-) and chaired an organising committee for a 2010 symposium on Cardiology at the RCPE. I am Chair of the
organisation and programme committee for the Royal College of Physicians of Edinburgh Consensus Conference on Atrial Fibrillation,
planned for 2012 – this includes education and teaching sessions and workshops, for participants.
I currently write for UpToDate [a popular resource for teaching/education] and Clinical Evidence [both updated 2-3x/yr]. More recently, I
have advised and written for BMJ Point of Care (2010-), and the Royal College of Physicians Map of Medicine (2010-, atrial fibrillation
section). I co-authored the AF chapter for the ESC Textbook of Cardiovascular Medicine (which serves as core curriculum for European
cardiologists, 2nd edition published in 2009).
I have supervised approximately 40 higher degree (MD/PhD/MPhil) since 1997 [8 since 2009] and regularly examine at under/postgraduate
exams and as an external examiner, both nationally and internationally (eg. Hong Kong (2005-ongoing), Copenhagen (2010), Aarhus (2010),
Amsterdam (2011)], Maastricht (2012), Warwick (2012) etc).
ACADEMIC CITIZENSHIP
In 2009, I was appointed Visiting Professor in Aston University, Birmingham. In 2011, I was conferred the title of Adjunct Professor in
Aalborg University, Denmark – for research and teaching. In April 2013, I was awarded an honorary doctorate doctor medicinae honoris
causa from Aalborg University.
I have Chaired various task forces for the European Society of Cardiology, European Heart Rhythm Association (EHRA) and European Heart
Failure Association, and was on various national/international guideline writing committees (see above). I recently served on the scientific
documents committee (2009-2011) and scientific initiatives committed (2011-) of EHRA.
I am currently on the programme committee for the Cardiostim and Europace meetings (2011-), being the major scientific meetings of EHRA.
I was Chair of the organisation and programme committee for the Royal College of Physicians of Edinburgh Consensus Conference on Atrial
Fibrillation, March 2012.
I have been invited as an ‘international technical expert’ in a Duke University Evidence-based Practice Center report "Stroke Prevention in
Atrial Fibrillation", in partnership with the Agency for Healthcare Research and Quality (AHRQ) (USA, 2011-12).
I was appointed to be part of a multinational evaluation committee on behalf of the German government funding, for the Review Board
Meeting to assess the Mainz Thrombosis Centre (TZM) proposal by the University Medical Centre Mainz (UMCM) (2009-2010). I was a
consortium member of the Science City Advantage West Midlands multidisciplinary Translational Medicine Research Infrastructure bid,
jointly awarded to the Universities of Birmingham and Warwick (2009 - £9m).
4
I was cardiovascular lead for the Birmingham and Black Country Comprehensive Local Research Network (BBC CLRN) from 2010-2011. I
was appointed UK Chief Investigator for 2 major non-industry academic multinational projects – the National Institutes for Health NINDS
[cooperative agreements U01 NS43975 and U01 NS39143], USA, for WARCEF (Warfarin versus Aspirin in Reduced Cardiac Ejection
Fraction) study (2009-), and more recently, the Netherlands Heart Foundation funded RACE-3 trial (Routine vs Aggressive Upstream rhythm
control for prevention of early atrial fibrillation in heart failure), starting 2011.
I am a regular peer reviewer for research grants for the Medical Research Council, British Heart Foundation, Wellcome Trust, Canadian
Institutes for Health Research (CIHR), Hong Kong Research Council, etc (2009-ongoing). I currently serve as data safety management board
(DSMB) member for a Canadian Institutes for Health Research (CIHR) funded trial – BRUISE (2009-ongoing).
I have regularly acted as peer reviewer for academic promotion applicants from national/international universities [eg. University of Vienna,
Austria; Johns Hopkins University in Baltimore, USA; University of Hong Kong; University of Singapore, etc] (2009-ongoing).
I have been peer reviewer for various guidelines and position documents for the European Society of Cardiology and European Heart Rhythm
Association. I was a peer reviewer for the National Practice Guidelines on AF for Malaysia (2011). I was appointed as one of the expert
international reviewers for the 2012 Heart Rhythm Society/European Heart Rhythm Association/ European Cardiac Arrhythmia Society
(HRS/EHRA/ECAS) Expert Consensus Statement on Catheter and Surgical Ablation of Atrial Fibrillation (due 2012).
I am on the expert medical advisory committee (with other international experts on AF) for 2 major international patient organisations
involved in atrial fibrillation – the AF Association (http://www.atrialfibrillation.org.uk) and Stopafib.org (http://stopafib.org) (both 2009-).
I am West Midlands regional advser for the Royal College of Physicians of Edinburgh (2013).
5